Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Slavisa  Ninkovic; Nicholas E.  Murphy; Hasib  Sidiqi; Craig Thomas Wallington-Beddoe; Anish  Puliyayil; Costas K.  Yannakou; Wojt Janowski; Flora Yuen; Andrew Spencer; Hang Quach

doi:10.1182/blood-2021-151871

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

Slavisa Ninkovic, Nicholas E. Murphy, Hasib Sidiqi, Craig Thomas Wallington-Beddoe, Anish Puliyayil, Costas K. Yannakou, Wojt Janowski, Flora Yuen, Andrew Spencer, Hang Quach

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Background: Almost two thirds of transplant-ineligible, treatment naïve multiple myeloma (NDMM, TNE) patients (pts) do not proceed to second line anti-MM therapy. Given depth of response to initial therapy correlates to overall survival (OS), a deep remission should also be the target for this cohort of generally elderly and frail patients. However, this should not come at the expense of either treatment-related or fiscal toxicity. IRIL is a phase II, multicentre, response-adapted study examining treatment intensification with isatuximab (Isa; supported by Sanofi/Genzyme), an anti-CD38 monoclonal antibody, for pts not achieving pre-defined target responses to lenalidomide and dexamethasone (Rd).

Original language	English
Article number	1671
Number of pages	2
Journal	Blood
Volume	138
Issue number	Supplement 1
DOIs	https://doi.org/10.1182/blood-2021-151871
Publication status	Published - Nov 2021
Externally published	Yes

Keywords

myeloma
remission
isatuximab
lenalidomide
dexamethasone

Access to Document

10.1182/blood-2021-151871Licence: In Copyright

Cite this

Ninkovic, S., Murphy, N. E., Sidiqi, H., Wallington-Beddoe, C. T., Puliyayil, A., Yannakou, C. K., Janowski, W., Yuen, F., Spencer, A., & Quach, H. (2021). Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02). Blood, 138(Supplement 1), Article 1671. https://doi.org/10.1182/blood-2021-151871

@article{274d253522f940509370249d23221b8c,

title = "Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)",

abstract = "Background: Almost two thirds of transplant-ineligible, treatment na{\"i}ve multiple myeloma (NDMM, TNE) patients (pts) do not proceed to second line anti-MM therapy. Given depth of response to initial therapy correlates to overall survival (OS), a deep remission should also be the target for this cohort of generally elderly and frail patients. However, this should not come at the expense of either treatment-related or fiscal toxicity. IRIL is a phase II, multicentre, response-adapted study examining treatment intensification with isatuximab (Isa; supported by Sanofi/Genzyme), an anti-CD38 monoclonal antibody, for pts not achieving pre-defined target responses to lenalidomide and dexamethasone (Rd).",

keywords = "myeloma, remission, isatuximab, lenalidomide, dexamethasone",

author = "Slavisa Ninkovic and Murphy, {Nicholas E.} and Hasib Sidiqi and Wallington-Beddoe, {Craig Thomas} and Anish Puliyayil and Yannakou, {Costas K.} and Wojt Janowski and Flora Yuen and Andrew Spencer and Hang Quach",

year = "2021",

month = nov,

doi = "10.1182/blood-2021-151871",

language = "English",

volume = "138",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "Supplement 1",

}

Ninkovic, S, Murphy, NE, Sidiqi, H, Wallington-Beddoe, CT, Puliyayil, A, Yannakou, CK, Janowski, W, Yuen, F, Spencer, A & Quach, H 2021, 'Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)', Blood, vol. 138, no. Supplement 1, 1671. https://doi.org/10.1182/blood-2021-151871

Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02). / Ninkovic, Slavisa ; Murphy, Nicholas E. ; Sidiqi, Hasib et al.
In: Blood, Vol. 138, No. Supplement 1, 1671, 11.2021.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma

T2 - Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)

AU - Ninkovic, Slavisa

AU - Murphy, Nicholas E.

AU - Sidiqi, Hasib

AU - Wallington-Beddoe, Craig Thomas

AU - Puliyayil, Anish

AU - Yannakou, Costas K.

AU - Janowski, Wojt

AU - Yuen, Flora

AU - Spencer, Andrew

AU - Quach, Hang

PY - 2021/11

Y1 - 2021/11

N2 - Background: Almost two thirds of transplant-ineligible, treatment naïve multiple myeloma (NDMM, TNE) patients (pts) do not proceed to second line anti-MM therapy. Given depth of response to initial therapy correlates to overall survival (OS), a deep remission should also be the target for this cohort of generally elderly and frail patients. However, this should not come at the expense of either treatment-related or fiscal toxicity. IRIL is a phase II, multicentre, response-adapted study examining treatment intensification with isatuximab (Isa; supported by Sanofi/Genzyme), an anti-CD38 monoclonal antibody, for pts not achieving pre-defined target responses to lenalidomide and dexamethasone (Rd).

AB - Background: Almost two thirds of transplant-ineligible, treatment naïve multiple myeloma (NDMM, TNE) patients (pts) do not proceed to second line anti-MM therapy. Given depth of response to initial therapy correlates to overall survival (OS), a deep remission should also be the target for this cohort of generally elderly and frail patients. However, this should not come at the expense of either treatment-related or fiscal toxicity. IRIL is a phase II, multicentre, response-adapted study examining treatment intensification with isatuximab (Isa; supported by Sanofi/Genzyme), an anti-CD38 monoclonal antibody, for pts not achieving pre-defined target responses to lenalidomide and dexamethasone (Rd).

KW - myeloma

KW - remission

KW - isatuximab

KW - lenalidomide

KW - dexamethasone

U2 - 10.1182/blood-2021-151871

DO - 10.1182/blood-2021-151871

M3 - Meeting Abstract

SN - 0006-4971

VL - 138

JO - Blood

JF - Blood

IS - Supplement 1

M1 - 1671

ER -

Ninkovic S, Murphy NE, Sidiqi H, Wallington-Beddoe CT, Puliyayil A, Yannakou CK et al. Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02). Blood. 2021 Nov;138(Supplement 1):1671. doi: 10.1182/blood-2021-151871